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Patients with nodal/paranodal antibodies represent a specific subgroup of inflammatory pe-
ripheral neuropathies, whose clinical presentation with a prolonged subacute phase, additional
symptoms such as ataxia and tremor, and poor treatment response to IV immunoglobulin
(IVIG) often differs from classic Guillain-Barré syndrome (GBS) or chronic inflammatory
demyelinating polyneuropathy (CIDP).1
Previous studies on nodo/paranodopathies mainly focused on adult patients, whereas the
clinical spectrum of pediatric patients is less well established. We reviewed the clinical pre-
sentation of 54 children with GBS (n = 42) and CIDP (n = 12) and retrospectively screened for
antibodies against neurofascin155 (NF155), NF186, NF140, contactin-1 (CNTN1), contactin-
associated protein1 (CASPR1), and glycine-receptor (GlyR) using cell-based assays2,3; 1 pa-
tient was additionally tested with CNTN1-ELISA.4 All cases with sufficient serum were tested
for ganglioside-IgG-, IgA-, and IgM-antibodies against GM1 (n = 42), GD1a (n = 18), GD1b (n
= 23), and GQ1b (n = 21).5 Clinical and paraclinical information of all patients is summarized
in the table. The study was approved by the ethics committee (EK1773/2016).
Children with classic GBS
Of 42 children with GBS, 26 were classified as acute inflammatory demyelinating poly-
neuropathy (AIDP), 7 as acute motor/motor-sensory axonal neuropathy (AMAN/AMSAN)
by nerve conduction velocity according to Hadden criteria,6 4 as Miller-Fisher syndrome
(MFS), and 2 as MFS/GBS overlap. Three patients with GBS could not be classified because of
lack of nerve-conduction studies. In 25 of 35 patients (71.4%), an infection was reported within
4 weeks before symptom onset (13 gastrointestinal, 4 respiratory, and 8 unspecified). Eight
patients had IgG-ganglioside antibodies (19.0%), 6 IgM (14.2%), and 1 IgA (2.4%). Nodal/
paranodal antibodies were not detected. Patients with AMAN/AMSAN (5/7 with reported
infection: 1 campylobacter jejuni, 1 varicella-zoster virus, and 3 unspecified) were more often
ganglioside antibody positive (6/7) than patients with AIDP (4/26; likelihood ratio 12.419) or
MFS (2/4).
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Table Clinical and paraclinical data of patients with GBS and CIDP





No. of patients 15 27 5 7
Age mean (range) 11.6 (4–17) 10.22 (1–18) 7.9 (3–11) 10.4 (4–18)
Gender m:f 9:6 15:12 3:2 4:3
AIDP 4 22
AMAN/AMSAN 6 1
MFS/MFS overlap 3/1 1/1
GBS no NCS 1 2
GM1+ 6 — 0 0
GD1a+ 1 0 0
GD1b+ 1 0 0
GM1+GD1b+ 4 0 0
GQ1b+ 1 0 0
GM1+GD1a+ GQ1b+ 1
GD1a+GQ1b+ 1
Pan-neurofascin+ — — 2 0
NF155+ 1 0
CNTN1+ 2 0
CSF mean cell count/μL (range) 3.15 (0–11) 2.92 (0–11) 4.6 (0–21) 3.8 (1–9)
CSF mean total protein mg/dL (range) 98.08 (10–250) 118.59 (19–401) 292.4 (75–619) 107.7 (24–288)
Infection (data available from 45/54) 11 (2 C. jejuni; 1 VZV; 8
unspecified)
14 (2 C. jejuni; 3 VZV; 1 EBV; 8
unspecified)
1 2
GI 6 7 1 0
Respiratory 2 2 0 2
Other 3 5 0 0
Infection d prior mean (range) 9 (1–14) 11.6 (3–28) 0 4.8 (1–10)
Days hospitalization mean (range) 13.43 (3–30) 20.73 (0–135) 13 (2–28) 10.4 (2–16)
Cranial nerve involvement 3 7 1 2
Autonomic dysfunction 1 2 0 0
Tremor/ataxia 3 3 5 1
OutcomemRS (available from 32/42 GBS
and 11/12 CIDP)
11mRS 0–1; 1mRS 2–4;
1 mRS >1;
15mRS 0–1; 4mRS 2–4; 1mRS
5–6; 5 mRS >1;
2 mRS 0–1; 3 mRS 2–4;
3 mRS >1;
2 mRS 0–1; 4 mRS
2–4; 4 mRS >1;
Severity at nadir HS (available from 41/
42 GBS and 12/12 CIDP)
2 HS1; 8 HS2; 1 HS3; 2
HS4; 1 HS5
2 HS1; 5 HS2; 7 HS3; 6 HS4; 6
HS5; 1 HS6
3 HS3; 2 HS4 2 HS1; 1 HS2; 4 HS4
Abbreviations: AIDP = acute inflammatory demyelinating polyneuropathy; AMAN = acute motor axonal neuropathy; AMSAN = acute motor and sensory
axonal neuropathy; C. jejuni = campylobacter jejuni; CIDP = chronic inflammatory demyelinating polyneuropathy; EBV = Epstein-Barr virus; GBS = Guillain-
Barré syndrome; GI = gastrointestinal; HS = Hughes score; MFS =Miller-Fisher syndrome; mRS =modified Rankin Scale; NCS = nerve-conduction study; VZV =
varicella-zoster-virus.
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Children with nodal/
paranodal antibodies
Five of 12 children, who met the EFNS/PNS criteria for CIDP,
had nodal/paranodal antibodies: 2 pan-neurofascin (NF155/
NF186/140 triple positive), 1 NF155, and 2 CNTN1-
antibodies. The IgG-subclass distribution was determined by
flow cytometry analysis.7 IgG4 was the predominant subclass in
all patients and ranged from 75% to 100%. In addition, 1 patient
with pan-neurofascin-antibodies tested positive for GlyR-
antibodies but did not develop stiff-person syndrome or pro-
gressive encephalomyelitis with rigidity, and the significance of
this finding needs further investigation. The mean age was 7.9
years (range 3–11), and the male:female ratio was 3:2. The
median duration of hospitalization was 13 days (range 2–28).
One pan-neurofascin-patient was initially diagnosed as GBS and
reclassified as CIDP during disease course, the other patients
had a chronic onset with slow progression over months or years.
One child had a gastrointestinal infection before symptom
onset. One CNTN1-patient showed cranial nerve involvement
and optic neuritis during disease course. All children had ataxia,
4 neuropathic pain (all except 1 pan-neurofascin), and 3 (2
CNTN1, and 1 pan-neurofascin) tremor. At the peak of disease,
3 children needed a walking aid (Hughes 3) and 2 were bed-
ridden (Hughes 4). None of the children had renal dysfunction.
The mean CSF white cell count was 4.6 μL (range 0–21), and
the mean CSF protein was 292.4 mg/dL (range 75–619).
The mean time of follow-up was 32 months (range 17–57).
The 2 CIDP patients with pan-neurofascin-antibodies initially
showed no or only partial response to IVIG and therefore
received corticosteroids, 1 along with plasma exchange and the
other with mycophenolate. Both recovered only very slowly
over up to 4 years with a modified Rankin Scale (mRS) score of
1 at the last follow-up. The NF155-patient did not respond to
IVIG and corticosteroids and subsequently received immu-
noadsorption and rituximab, leading to significant clinical im-
provement. After 8 months, he relapsed in association with
normalization of the CD19/20 ratio and again rapidly im-
proved after another dose of rituximab, with amRS score of 2 at
the last follow-up. One patient with CNTN1-antibodies
worsened despite monthly IVIG and corticosteroids given
over 4 months. After treatment was switched to rituximab, he
improved rapidly in the following weeks and remained stable
since then. The second child with CNTN1-antibodies showed
only partial response to IVIG with relapses in conjunction with
infections. This child improved significantly after rituximab
application with a mRS score of 2 at the last follow-up.
In summary, our study demonstrates that nodal/paranodal
antibodies occur in a subgroup of paediatric patients with
CIDP, but not GBS. Children with AMAN/AMSAN fre-
quently have ganglioside antibodies. Children with CIDP and
atypical/prolonged disease course with high Hughes score
(>2), sensory ataxia, prominent neuropathic pain, and tremor
may have nodal/paranodal antibodies. These patients often
do not sufficiently respond to IVIG, whereas in our case series,
rituximab led to prompt improvement in 3 children. Optimal
treatment strategies for children with nodal/paranodal anti-
bodies have to be further determined in larger studies.
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(R. Höftberger, M.Winklehner) and I3334-B27 (R. Höftberger),
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